OverviewSuggest Edit

Axonics Modulation Technologies is a medical device company developing a neuromodulation platform based on miniaturized rechargeable technology directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. The Axonics Sacral Neuromodulation System is a CE-marked rechargeable SNM system designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.

TypePublic
Founded2013
HQIrvine, CA, US
Websiteaxonics.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2019)302(+248%)
Job Openings15
Revenue (FY, 2020)$111.5 M(+709%)
Share Price (Dec 2021)$56
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Axonics

Erik Amble

Erik Amble

Director
Guangqiang Jiang

Guangqiang Jiang

Chief Technology Officer
Juliet Tammenoms Bakker

Juliet Tammenoms Bakker

Director
Rinda Sama

Rinda Sama

Chief Operating Officer
Michael H. Carrel

Michael H. Carrel

Independent Director
Karen Noblett

Karen Noblett

Chief Medical Officer
Show more

Axonics Office Locations

Axonics has an office in Irvine
Irvine, CA, US (HQ)
26 Technology Dr
Show all (1)

Axonics Financials and Metrics

Axonics Revenue

Axonics's revenue was reported to be $111.54 m in FY, 2020
USD

Revenue (Q1, 2021)

34.4m

Gross profit (Q1, 2021)

20.4m

Gross profit margin (Q1, 2021), %

59.3%

Net income (Q1, 2021)

(22.5m)

EBIT (Q1, 2021)

(21.6m)

Market capitalization (31-Dec-2021)

2.6b

Closing stock price (31-Dec-2021)

56.0

Cash (31-Mar-2021)

131.0m

EV

2.6b
Axonics's current market capitalization is $2.6 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

128.1k707.0k13.8m111.5m

Cost of goods sold

117.9k356.0k6.5m44.4m

Gross profit

10.2k351.0k7.3m67.1m

Gross profit Margin, %

8%50%53%60%
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

128.0k201.0k1.1m1.5m1.3m26.3m15.2m35.2m34.4m

Cost of goods sold

118.0k106.0k548.0k772.0k632.0k9.9m8.5m13.4m14.0m

Gross profit

10.0k95.0k552.0k716.0k668.0k16.4m6.7m21.8m20.4m

Gross profit Margin, %

8%47%50%48%51%62%44%62%59%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.2m24.4m98.3m171.1m241.2m

Accounts Receivable

427.0k7.9m18.3m

Prepaid Expenses

520.2k979.7k3.7m4.5m5.4m

Inventories

1.5m3.7m15.7m63.1m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

24.7m20.1m89.3m82.7m76.2m159.8m287.7m269.3m131.0m

Accounts Receivable

13.6k219.0k804.0k1.3m954.0k20.8m14.1m17.7m21.5m

Prepaid Expenses

1.6m1.8m2.8m3.1m2.6m4.2m3.6m3.2m4.7m

Inventories

1.9m2.1m5.1m8.0m12.7m19.2m30.1m44.3m71.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(17.4m)(18.1m)(32.5m)(79.9m)(54.9m)

Depreciation and Amortization

625.1k725.4k946.0k1.2m1.7m

Inventories

(1.5m)(2.3m)(12.0m)(47.4m)

Accounts Payable

(1.0m)985.4k1.8m2.4m4.8m
Quarterly
USDQ2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(8.6m)(13.1m)(15.3m)(22.8m)(13.1m)(32.2m)(57.2m)(14.6m)(34.4m)(43.6m)(22.5m)

Depreciation and Amortization

334.7k514.0k427.6k663.0k276.0k570.0k880.0k380.0k806.0k1.3m1.1m

Inventories

(519.2k)(813.0k)(371.9k)(607.0k)(1.4m)(4.3m)(9.0m)(3.6m)(14.4m)(28.6m)(7.2m)

Accounts Payable

453.5k498.0k471.7k367.0k(1.3m)(881.0k)796.0k1.6m4.8m3.5m914.0k
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Axonics Operating Metrics

Q3, 2018

Patent Applications

76

Patents Issued

37

Patients Reached

180
Show all operating metrics

Axonics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Axonics Online and Social Media Presence

Embed Graph

Axonics Blogs

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue Content Import Thu, 01/06/2022 - 06:01 Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue January 6, 2022 at 6:00 AM EST This release is a backfill from a News Wire …

Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council

IRVINE, Calif. --(BUSINESS WIRE)--Nov. 30, 2021-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Raymond W.

Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™

Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™ Content Import Wed, 11/17/2021 - 06:01 Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™ November 17, 2021 at 6:00 AM E…

Axonics® Reports Third Quarter 2021 Financial Results

IRVINE, Calif. --(BUSINESS WIRE)--Nov. 4, 2021-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the third quarter ended September 30,

Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County

IRVINE, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has been named by the Orange County Business Journal as the fastest growing

Axonics® to Report Third Quarter 2021 Financial Results on November 4

Axonics® to Report Third Quarter 2021 Financial Results on November 4 Content Import Thu, 10/07/2021 - 07:00 Axonics® to Report Third Quarter 2021 Financial Results on November 4 October 7, 2021 at 7:00 AM EDT This release is a backfill from a News Wire …
Show more

Axonics Frequently Asked Questions

  • When was Axonics founded?

    Axonics was founded in 2013.

  • Who are Axonics key executives?

    Axonics's key executives are Erik Amble, Guangqiang Jiang and Juliet Tammenoms Bakker.

  • How many employees does Axonics have?

    Axonics has 302 employees.

  • What is Axonics revenue?

    Latest Axonics annual revenue is $111.5 m.

  • What is Axonics revenue per employee?

    Latest Axonics revenue per employee is $369.3 k.

  • Who are Axonics competitors?

    Competitors of Axonics include TEMA SINERGIE, BSN Medical and Acelity.

  • Where is Axonics headquarters?

    Axonics headquarters is located at 26 Technology Dr, Irvine.

  • Where are Axonics offices?

    Axonics has an office in Irvine.

  • How many offices does Axonics have?

    Axonics has 1 office.